vs
Side-by-side financial comparison of AtriCure, Inc. (ATRC) and TELEFLEX INC (TFX). Click either name above to swap in a different company.
TELEFLEX INC runs the higher net margin — 177.8% vs 0.1%, a 177.7% gap on every dollar of revenue. On growth, AtriCure, Inc. posted the faster year-over-year revenue change (14.3% vs -150.5%). Over the past eight quarters, TELEFLEX INC's revenue compounded faster (NaN% CAGR vs NaN%).
AtriCure, Inc. is a global medical device company specializing in the research, development, and manufacturing of innovative surgical tools and therapeutic solutions for treating atrial fibrillation and associated cardiac conditions. Its core customers include hospitals, cardiac surgery centers, and healthcare providers across North America, Europe, and the Asia Pacific region, with products designed to support safer, more effective minimally invasive cardiac procedures.
Teleflex Incorporated, headquartered in Wayne, Pennsylvania, is an American provider of specialty medical devices for a range of procedures in critical care and surgery. Teleflex has annual revenues of $2.4 billion, operations in 40 countries, and more than 15,000 employees. By 2011, the company had substantially realigned to focus on its current business as a medical-device manufacturer, having undergone several years of active acquisitions and divestitures. Teleflex has been associated with...
ATRC vs TFX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $141.2M | $-401.9M |
| Net Profit | $108.0K | $-714.3M |
| Gross Margin | 77.4% | — |
| Operating Margin | 23.0% | — |
| Net Margin | 0.1% | 177.8% |
| Revenue YoY | 14.3% | -150.5% |
| Net Profit YoY | — | -422.7% |
| EPS (diluted) | $0.00 | $-15.85 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $141.2M | — | ||
| Q4 25 | $140.5M | $-401.9M | ||
| Q3 25 | $134.3M | $913.0M | ||
| Q2 25 | $136.1M | $780.9M | ||
| Q1 25 | $123.6M | $700.7M | ||
| Q4 24 | $124.3M | $795.4M | ||
| Q3 24 | $115.9M | $764.4M | ||
| Q2 24 | $116.3M | $749.7M |
| Q1 26 | $108.0K | — | ||
| Q4 25 | — | $-714.3M | ||
| Q3 25 | $-267.0K | $-408.9M | ||
| Q2 25 | $-6.2M | $122.6M | ||
| Q1 25 | $-6.7M | $95.0M | ||
| Q4 24 | — | $-136.7M | ||
| Q3 24 | $-7.9M | $111.0M | ||
| Q2 24 | $-8.0M | $80.0M |
| Q1 26 | 77.4% | — | ||
| Q4 25 | 75.0% | — | ||
| Q3 25 | 75.5% | 49.5% | ||
| Q2 25 | 74.5% | 55.2% | ||
| Q1 25 | 74.9% | 55.6% | ||
| Q4 24 | 74.5% | 55.3% | ||
| Q3 24 | 74.9% | 56.3% | ||
| Q2 24 | 74.7% | 55.6% |
| Q1 26 | 23.0% | — | ||
| Q4 25 | 1.8% | — | ||
| Q3 25 | 0.2% | -44.8% | ||
| Q2 25 | -4.5% | 19.9% | ||
| Q1 25 | -4.8% | 17.9% | ||
| Q4 24 | -11.7% | -13.9% | ||
| Q3 24 | -6.4% | 19.5% | ||
| Q2 24 | -6.2% | 15.6% |
| Q1 26 | 0.1% | — | ||
| Q4 25 | — | 177.8% | ||
| Q3 25 | -0.2% | -44.8% | ||
| Q2 25 | -4.5% | 15.7% | ||
| Q1 25 | -5.5% | 13.6% | ||
| Q4 24 | — | -17.2% | ||
| Q3 24 | -6.8% | 14.5% | ||
| Q2 24 | -6.9% | 10.7% |
| Q1 26 | $0.00 | — | ||
| Q4 25 | $0.04 | $-15.85 | ||
| Q3 25 | $-0.01 | $-9.24 | ||
| Q2 25 | $-0.13 | $2.77 | ||
| Q1 25 | $-0.14 | $2.07 | ||
| Q4 24 | $-0.33 | $-2.89 | ||
| Q3 24 | $-0.17 | $2.36 | ||
| Q2 24 | $-0.17 | $1.69 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $146.2M | $378.6M |
| Total DebtLower is stronger | $61.0M | $2.6B |
| Stockholders' EquityBook value | $491.7M | $3.1B |
| Total Assets | $644.0M | $6.9B |
| Debt / EquityLower = less leverage | 0.12× | 0.85× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $146.2M | — | ||
| Q4 25 | $167.4M | $378.6M | ||
| Q3 25 | $147.9M | $354.0M | ||
| Q2 25 | $117.8M | $253.7M | ||
| Q1 25 | $99.9M | $284.1M | ||
| Q4 24 | $122.7M | $290.2M | ||
| Q3 24 | $130.3M | $243.2M | ||
| Q2 24 | $114.0M | $238.6M |
| Q1 26 | $61.0M | — | ||
| Q4 25 | — | $2.6B | ||
| Q3 25 | $61.9M | $2.7B | ||
| Q2 25 | $61.9M | $1.9B | ||
| Q1 25 | $61.9M | $1.9B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | $61.9M | — | ||
| Q2 24 | $61.9M | — |
| Q1 26 | $491.7M | — | ||
| Q4 25 | $491.9M | $3.1B | ||
| Q3 25 | $476.5M | $3.8B | ||
| Q2 25 | $464.5M | $4.2B | ||
| Q1 25 | $454.6M | $4.1B | ||
| Q4 24 | $461.0M | $4.3B | ||
| Q3 24 | $465.0M | $4.5B | ||
| Q2 24 | $462.1M | $4.6B |
| Q1 26 | $644.0M | — | ||
| Q4 25 | $654.2M | $6.9B | ||
| Q3 25 | $635.4M | $7.9B | ||
| Q2 25 | $608.8M | $7.4B | ||
| Q1 25 | $591.6M | $7.2B | ||
| Q4 24 | $609.3M | $7.1B | ||
| Q3 24 | $615.1M | $7.5B | ||
| Q2 24 | $597.3M | $7.4B |
| Q1 26 | 0.12× | — | ||
| Q4 25 | — | 0.85× | ||
| Q3 25 | 0.13× | 0.70× | ||
| Q2 25 | 0.13× | 0.45× | ||
| Q1 25 | 0.14× | 0.47× | ||
| Q4 24 | — | 0.39× | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-92.3M |
| Free Cash FlowOCF − Capex | — | $-92.9M |
| FCF MarginFCF / Revenue | — | 23.1% |
| Capex IntensityCapex / Revenue | — | -0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.4M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $20.0M | $-92.3M | ||
| Q3 25 | $26.7M | $107.8M | ||
| Q2 25 | $21.6M | $7.8M | ||
| Q1 25 | $-11.0M | $73.3M | ||
| Q4 24 | $5.8M | $202.6M | ||
| Q3 24 | $20.0M | $231.1M | ||
| Q2 24 | $7.4M | $91.7M |
| Q1 26 | — | — | ||
| Q4 25 | $18.4M | $-92.9M | ||
| Q3 25 | $24.1M | $77.8M | ||
| Q2 25 | $19.0M | $-26.8M | ||
| Q1 25 | $-13.2M | $43.3M | ||
| Q4 24 | $3.1M | $170.6M | ||
| Q3 24 | $16.4M | $209.9M | ||
| Q2 24 | $5.0M | $56.9M |
| Q1 26 | — | — | ||
| Q4 25 | 13.1% | 23.1% | ||
| Q3 25 | 18.0% | 8.5% | ||
| Q2 25 | 13.9% | -3.4% | ||
| Q1 25 | -10.7% | 6.2% | ||
| Q4 24 | 2.5% | 21.4% | ||
| Q3 24 | 14.1% | 27.5% | ||
| Q2 24 | 4.3% | 7.6% |
| Q1 26 | — | — | ||
| Q4 25 | 1.1% | -0.2% | ||
| Q3 25 | 1.9% | 3.3% | ||
| Q2 25 | 2.0% | 4.4% | ||
| Q1 25 | 1.8% | 4.3% | ||
| Q4 24 | 2.2% | 4.0% | ||
| Q3 24 | 3.1% | 2.8% | ||
| Q2 24 | 2.1% | 4.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.06× | ||
| Q1 25 | — | 0.77× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.08× | ||
| Q2 24 | — | 1.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATRC
| Appendage management | $48.4M | 34% |
| Open ablation | $39.1M | 28% |
| Other | $25.0M | 18% |
| Pain management | $22.4M | 16% |
| Minimally invasive ablation | $6.4M | 5% |
TFX
Segment breakdown not available.
